Metagenomi Therapeutics (MGX) Non-Current Deffered Revenue (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $1.6 million, down 62.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 62.6% YoY), and the FY2025 annual result was $3.0 million, down 70.8% from the prior year.
• Non-Current Deffered Revenue retreated to $1.6 million in Q1 2026 per MGX's latest filing, from $3.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $30.9 million in Q4 2023 and troughed at $1.6 million in Q1 2026.
• A 4-year average of $10.6 million and a median of $7.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue sank 84.75% in 2025, then sank 62.6% in 2026.
• A 4-year view of Non-Current Deffered Revenue shows it stood at $30.9 million in 2023, then tumbled by 66.9% to $10.2 million in 2024, then sank by 70.8% to $3.0 million in 2025, then plunged by 45.3% to $1.6 million in 2026.
• Business Quant data shows MGX's Non-Current Deffered Revenue at $1.6 million in Q1 2026, $3.0 million in Q4 2025, and $1.9 million in Q3 2025.